Pricing Log in Create free account

Biohaven Ltd. (BHVN) vs Hemab Therapeutics Holdings, Inc. (COAG)

Biohaven Ltd. and Hemab Therapeutics Holdings, Inc. are both Biotechnology companies. Biohaven Ltd. and Hemab Therapeutics Holdings, Inc. are of similar size ($2.1B and $2.1B). Across the 7 metrics below, Hemab Therapeutics Holdings, Inc. leads on 4 and Biohaven Ltd. on 3.

Valuation

Metric BHVN COAG Biotechnology median
P/E n/m n/m 10.60
P/S 2.19 n/m 9.40
P/B n/m 3.22 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 2.30 n/m 9.02
Earnings yield (26.67%) (110.83%) (32.88%)
Free cash flow yield (22.56%) (4.97%) (23.13%)

Profitability

Metric BHVN COAG Biotechnology median
Gross margin 0.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 940.46% 0.00% (51.96%)
Return on assets (161.32%) (31.79%) (46.06%)
Return on invested capital (6,659.91%) 0.00% 0.00%

Growth

Metric BHVN COAG Biotechnology median
Revenue growth (TTM) 425.20% — 6.76%
EPS growth (last fiscal year) 26.08% — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BHVN COAG Biotechnology median
Debt to equity (2.69) 0.00 0.00
Current ratio 3.05 35.85 4.97
Net debt to EBITDA 0.11 — 1.01

Dividend

Metric BHVN COAG Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BHVN COAG Biotechnology median
Market cap 2.10b 2.13b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack